ST. LOUIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced several key hires to its Options and Equity Derivatives team, helping to enhance the depth and breadth of its product suite for institutional investors.

Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023 Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023

BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Multiple System Atrophy (MSA).

ACHESON, Alberta, Oct. 04, 2023 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG” or the “Company”) (TSX:NOA) today announced the closing of its acquisition of MacKellar Group (“MacKellar”), with an effective date of October 1, 2023. Total expected consideration is $395 million (the “Consideration”), with the final Consideration amount to be determined based on MacKellar’s audited financial statements as of September 30, 2023, which will be reflected in the Company’s financial statements for the year ending December 31, 2023. The Transaction was previously announced on July 26, 2023.

SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that H.C. Wainwright will be hosting a virtual medical expert webinar on October 11, 2023 at 12:00 p.m. Eastern Time to discuss the current treatment landscape for cancer-related anorexia and cachexia. The webinar will feature challenges and opportunities from a historical perspective and future strategies including Artelo’s lead candidate ART27.13 which is being developed as a supportive care therapy for people suffering from anorexia and weight loss associated with cancer. ARTL27.13 is currently undergoing a Phase 2a clinical trial for this potential indication.

The new larger facility will provide three new career training programs – Welding Technology, HVAC and Electrical and Electronic Systems Technology (EEST) – in addition to the Automotive Technology program offered at the current Philadelphia campus. The new larger facility will provide three new career training programs – Welding Technology, HVAC and Electrical and Electronic Systems Technology (EEST) – in addition to the Automotive Technology program offered at the current Philadelphia campus.

Celebrates recent spin-off and subsequent Nasdaq listing Celebrates recent spin-off and subsequent Nasdaq listing

ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): “The Past, The Present, and The Pipeline”, being held in New Orleans, Louisiana from October 14-18, 2023.

Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors

-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function -- -- Weight-loss drugs like Ozempic, Wegovy, Mounjaro and other GLP-1 drugs cause a significant loss of both fat and muscle; in older obese or overweight patients who may already have low muscle mass, the further drop in muscle mass of all-important muscles increases risk of muscle weakness, functional limitations, mobility disability, falls, higher hospitalizations, and greater mortality --